Phase 3 Completed N=140 Treatment

AGN-229666 Ophthalmic Solution for the Treatment of Seasonal or Perennial Allergic Conjunctivitis

Conjunctivitis, Allergic

Source: ClinicalTrials.gov NCT02082262 ↗

Enrolled (actual)

140

Serious AEs

0.0%

Results posted

Oct 2015

Primary outcomePrimary: Change From Baseline In Ocular Itching Frequency Score Using a 6-point Scale — 4.4; -3.4 Scores on a Scale

Summary

This study will evaluate the safety and efficacy of AGN-229666 for the treatment of seasonal or perennial allergic conjunctivitis.

Outcome Measures

Outcome	Result	p-value
PRIMARY Change From Baseline In Ocular Itching Frequency Score Using a 6-point Scale	4.4; -3.4	—

Eligibility Criteria

Inclusion Criteria

Japanese patients living in Japan with allergic conjunctivitis with itching and redness
Able and willing to discontinue wearing any contact lenses during the study period.

Exclusion Criteria

Eye surgical intervention and/or a history of refractive surgery within 6 months
History of retinal detachment, diabetic retinopathy, or progressive retinal disease
Presence of active eye infection (bacterial, viral, or fungal)
History of an eye herpetic infection
Use of corticosteroids within 6 months or anticipated use during the study.

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02082262). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.